Gruninger RH - Search Results

1

Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family.

Middleton SA, Johnson DL, Jin R, McMahon FJ, Collins A, Tullai J, Gruninger RH, Jolliffe LK, Mulcahy LS. Middleton SA, et al. Among authors: gruninger rh. J Biol Chem. 1996 Jun 14;271(24):14045-54. doi: 10.1074/jbc.271.24.14045. J Biol Chem. 1996. PMID: 8662939 Free article.

2

Erythropoietin receptor: application in drug development.

Jolliffe LK, Middleton SA, Barbone FP, Johnson DL, McMahon FJ, Lee WH, Gruninger RH, Mulcahy LS. Jolliffe LK, et al. Among authors: gruninger rh. Nephrol Dial Transplant. 1995;10 Suppl 2:28-34. doi: 10.1093/ndt/10.supp2.28. Nephrol Dial Transplant. 1995. PMID: 7644102

3

Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships.

Barbone FP, Middleton SA, Johnson DL, McMahon FJ, Tullai J, Gruninger RH, Schilling AE, Jolliffe LK, Mulcahy LS. Barbone FP, et al. Among authors: gruninger rh. J Biol Chem. 1997 Feb 21;272(8):4985-92. doi: 10.1074/jbc.272.8.4985. J Biol Chem. 1997. PMID: 9030560 Free article.

4

Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.

Kuo GH, Wang A, Emanuel S, Deangelis A, Zhang R, Connolly PJ, Murray WV, Gruninger RH, Sechler J, Fuentes-Pesquera A, Johnson D, Middleton SA, Jolliffe L, Chen X. Kuo GH, et al. Among authors: gruninger rh. J Med Chem. 2005 Mar 24;48(6):1886-900. doi: 10.1021/jm040099a. J Med Chem. 2005. PMID: 15771433

5

1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.

Lin R, Connolly PJ, Huang S, Wetter SK, Lu Y, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Rugg CA, Middleton SA, Jolliffe LK. Lin R, et al. Among authors: gruninger rh. J Med Chem. 2005 Jun 30;48(13):4208-11. doi: 10.1021/jm050267e. J Med Chem. 2005. PMID: 15974571

6

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.

Kuo GH, Deangelis A, Emanuel S, Wang A, Zhang Y, Connolly PJ, Chen X, Gruninger RH, Rugg C, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV. Kuo GH, et al. Among authors: gruninger rh. J Med Chem. 2005 Jul 14;48(14):4535-46. doi: 10.1021/jm040214h. J Med Chem. 2005. PMID: 15999992

7

Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

Kuo GH, Prouty C, Wang A, Emanuel S, Deangelis A, Zhang Y, Song F, Beall L, Connolly PJ, Karnachi P, Chen X, Gruninger RH, Sechler J, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV. Kuo GH, et al. Among authors: gruninger rh. J Med Chem. 2005 Jul 28;48(15):4892-909. doi: 10.1021/jm058205b. J Med Chem. 2005. PMID: 16033269

8

3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.

Lin R, Lu Y, Wetter SK, Connolly PJ, Turchi IJ, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Adams M, Pandey N, Moreno-Mazza S, Middleton SA, Jolliffe LK. Lin R, et al. Among authors: gruninger rh. Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4. doi: 10.1016/j.bmcl.2005.03.024. Bioorg Med Chem Lett. 2005. PMID: 15837297

9

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

Ho CY, Ludovici DW, Maharoof US, Mei J, Sechler JL, Tuman RW, Strobel ED, Andraka L, Yen HK, Leo G, Li J, Almond H, Lu H, DeVine A, Tominovich RM, Baker J, Emanuel S, Gruninger RH, Middleton SA, Johnson DL, Galemmo RA Jr. Ho CY, et al. Among authors: gruninger rh. J Med Chem. 2005 Dec 29;48(26):8163-73. doi: 10.1021/jm050680m. J Med Chem. 2005. PMID: 16366598

10

A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.

Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA. Emanuel S, et al. Among authors: gruninger rh. Mol Pharmacol. 2004 Sep;66(3):635-47. doi: 10.1124/mol.104.000638. Mol Pharmacol. 2004. PMID: 15322256

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters